Full-Time

Data Analytics Specialist

Updated on 8/15/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

A later, evening, or night shift may be required.

Bachelor's, Master's

Category
Data & Analytics (2)
,
Required Skills
LLM
Python
Data Visualization
R
Neural Networks
Apache Spark
SQL
Machine Learning
ETL
Data Engineering
Tableau
AWS
Data Modeling
Data Governance
Databricks
Data Analysis

Get referred to Amgen

See people who can refer or advise you

Requirements
  • A bachelor's degree with 8–12 years of experience in Computer Science, Information Technology, or a related field.
  • A bachelor's or master's degree in Computer Science, Software Engineering, Data Science, Statistics, or a similar field, or a bachelor's degree with 8 years of engineering or scientific experience.
  • Hands-on experience with big data technologies and platforms such as Databricks and Apache Spark, including PySpark, SparkSQL, workflow orchestration, and performance tuning on big data processing.
  • Hands-on experience with Python or R packages for exploratory data analysis, feature engineering, and machine-learning model training.
  • Proficiency in data analysis tools such as SQL and experience with data visualization tools such as Tableau.
  • Experience working with large, complex datasets.
  • A strong understanding of data governance frameworks, tools, and best practices.
  • Knowledge of data protection regulations and compliance requirements such as GDPR and CCPA.
  • Proven project-management skills and the ability to execute and manage complex projects and programs.
  • Ability to work in teams and serve as a technical mentor to junior team members.
  • Experience working effectively in a globally dispersed team environment.
  • Willingness and ability to work evening or night shifts, including second or third shifts, as required by business needs.
Responsibilities
  • Design, develop, and maintain data solutions for data generation, collection, and processing.
  • Assist with the design and development of data pipelines.
  • Create data pipelines and ensure data quality by implementing ETL processes to migrate and deploy data across systems.
  • Contribute to the design, development, and implementation of data pipelines, ETL/ELT processes, and data integration solutions.
  • Own data pipeline projects from inception to deployment, including scope, timelines, and risks.
  • Collaborate with cross-functional teams to understand data requirements and design solutions that meet business needs.
  • Develop and maintain data models, data dictionaries, and other documentation to ensure data accuracy and consistency.
  • Implement data security and privacy measures to protect sensitive data.
  • Use cloud platforms such as AWS to build scalable and efficient data solutions.
  • Collaborate with product teams and site and network teams to analyze and select data models and algorithms that generate insights and improve business processes or value.
  • Design, write, and test data, machine-learning, large-language-model, advanced analytics, visualization, and artificial-intelligence solutions.
  • Prioritize and lead the implementation of internally developed and externally provided analytic solutions.
  • Coordinate and project-manage the delivery and development of data, machine-learning, large-language-model, advanced analytics, visualization, and artificial-intelligence solutions.
  • Collect business requirements and user stories for new or enhanced analytic solutions.
  • Translate business requirements and pain points into machine-learning use cases addressing real-world business problems.
  • Implement current algorithms and approaches for machine learning.
  • Initiate and participate in prediction and optimization projects using advanced deep-learning, statistical, and mathematical approaches.
  • Provide technical oversight and guidance to other Data Analytics team members.
Desired Qualifications
  • Experience with ETL tools such as Apache Spark and Python packages for data processing and machine-learning model development.
  • A strong understanding of data modeling, data warehousing, and data integration concepts.
  • Knowledge of Python or R, Databricks, SageMaker, and cloud data platforms.
  • Certified Data Analyst certification, preferably on Databricks or cloud environments.
  • Certified Data Scientist certification, preferably on Databricks or cloud environments.
  • Machine-learning certification, preferably on Databricks or cloud environments.
  • Excellent critical-thinking and problem-solving skills.
  • Strong communication and collaboration skills.
  • Awareness of how to function in a team setting.
  • Presentation skills.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 10% to $10.1 billion; guidance increased to $38.2-$39.4 billion.
  • Repatha grew 37%, Evenity 38%, and Uplizna 90% in Q2 2026.
  • Colorado’s Enbrel price cap was blocked on July 1, 2026, preserving legacy cash flow.

What critics are saying

  • FDA proposed Tavneos withdrawal on April 27, 2026; a hearing loss kills ChemoCentryx economics.
  • Tavneos retraction and liver-injury findings threaten Amgen’s credibility with regulators and investigators in 2026.
  • Prolia erosion and patent battles, including Delaware’s June 2026 verdict, pressure margins until 2027.

What makes Amgen unique

  • MariTide’s monthly-to-quarterly dosing targets obesity convenience versus weekly GLP-1 rivals in 2027.
  • Amgen’s 2026 base is unusually diversified: Repatha, Evenity, Uplizna, Tezspire, and Imdelltra.
  • Amgen’s 2027 Hyderabad Science and Innovation Center expands AI-linked discovery capacity globally.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Aug 14th, 2026
Amgen and Regeneron emerge as GLP-1 investment alternatives beyond Eli Lilly and Novo Nordisk

Amgen and Regeneron could benefit from surging demand for GLP-1 drugs, which traditionally treated diabetes but now address obesity and obstructive sleep apnea. Amgen's stock is up 27% this year, with second-quarter revenue rising 10% year-over-year to $10.1 billion. The company is testing MariTide, an investigational GLP-1 medicine, in phase 3 studies for weight management and diabetes. MariTide could be administered monthly or less frequently, offering a convenience advantage over current daily or weekly treatments. Regeneron is also positioned to capitalise on the GLP-1 market expansion. Both companies present alternatives to current market leaders Eli Lilly and Novo Nordisk for investors seeking exposure to the growing GLP-1 drug category.

PR Newswire
Aug 12th, 2026
Amgen to open new science and innovation centre in Hyderabad's Genome Valley

Amgen announced plans to open a new Science and Innovation Center in Genome Valley, Hyderabad, expected to be operational in 2027. The facility will join Amgen's global Research and Development network of seven research laboratories, expanding the company's scientific capabilities. The center will bring together scientists and technologists across discovery chemistry, drug metabolism and pharmacokinetics, and precision medicine. It will integrate experimental science with data and digital innovation to accelerate the discovery and development of medicines. "The new center in Genome Valley expands the way we integrate experimental science with data and technology across our global research capabilities," said Jay Bradner, executive vice president of Research and Development, Artificial Intelligence and Data at Amgen. The facility will complement Amgen's existing technology and innovation site in Hyderabad.

Yahoo Finance
Aug 9th, 2026
Amgen fair value rises to $372 after Q2 beat sparks analyst target hikes to $450

Amgen's modeled fair value has risen from $352.23 to $371.93 per share following strong Q2 results and updated analyst targets. Several firms, including Scotiabank, TD Cowen, BMO Capital, and Oppenheimer, lifted price targets to around $450, citing earnings revisions and a diversified product portfolio. Bernstein noted a 6.8% revenue beat and 12.5% non-GAAP EPS beat in Q2, with raised full-year guidance driven by portfolio-wide execution. Strength came from products including Repatha, Tezspire, Uplizna, Evenity, and Imdelltra. However, Wells Fargo and Citi maintain cautious stances with Equal Weight and Neutral ratings, suggesting current performance may already be priced in. BofA kept its Underperform rating, describing 2026 as focused on execution ahead of key 2027 readouts.

Yahoo Finance
Aug 5th, 2026
Amgen beats Q2 forecast with $10.05B revenue, raises 2026 outlook despite obesity drug setback

Amgen reported second-quarter revenue of $10.05 billion, up 9% year on year, beating Wall Street expectations. Adjusted earnings reached $6.29 per share, surpassing the $5.62 consensus estimate. The biotech firm raised its full-year 2026 outlook, increasing expected revenue to $38.2 billion-$39.4 billion from $37.0 billion-$38.4 billion. Adjusted earnings guidance rose to $22.30-$23.50 per share. Repatha sales surged 37% to $953 million, whilst Evenity jumped 38% to $714 million. Rare-disease therapy Uplizna saw roughly 90% growth. These gains offset a 32% decline in Prolia sales due to biosimilar competition. Amgen discontinued obesity candidate AMG 513 but continues developing MariTide, with Phase 3 data expected in 2027. The stock trades at $406.17, approximately 14.75% above its estimated fair value.

PR Newswire
Aug 4th, 2026
Amgen reports 10% revenue growth to $10.1B in Q2 2026, driven by 26% surge in six key growth products

Amgen reported second quarter 2026 revenues of $10.1 billion, a 10% increase year-over-year. Product sales grew 9%, driven by volume growth across 22 products that achieved double-digit sales growth. The company's six key growth drivers grew 26% year-over-year, generating nearly 70% of second quarter product sales. GAAP earnings per share increased 65% to $4.37, whilst non-GAAP EPS rose 4% to $6.29. Notable product performance included Repatha sales increasing 37% to $953 million and EVENITY growing 38% to $714 million. The company generated $3.5 billion in free cash flow, compared to $1.9 billion in the prior year period. For full year 2026, Amgen expects total revenues between $38.2 billion and $39.4 billion, with non-GAAP EPS guidance of $22.30 to $23.50.